NCT04022382已完成不适用
A Single-Arm, Single-Center, Randomized, Single-Masked Study to Evaluate Restylane-Defyne for Punctal Occlusion in Participants With Mild to Moderate Dry Eye Disease
John C Meyer, MD2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2019年7月18日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Evaluating change in Schirmer score from baseline.
研究概览
简要总结
A study which participants with mild to moderate dry eye disease will have a punctum of one eye injected with 0.1ml Restylane Defyne and the other eye injected with 0.2ml Restylane Defyne. Participants will be evaluated over four visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •21 to 80 years of age
- •Baseline OSDI score of at least 13 with no more than 3 responses of "not applicable"
- •In both eyes, a baseline Schirmer test with anesthetic of ≤ 10mm/5 minutes
- •Literate, able to speak English and able to complete the questionnaire independently
- •Willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol.
排除标准
- •Use of ophthalmic cyclosporine or lifitegrast within 30 days prior to Day 0
- •History of surgical punctal occlusion (e.g., cautery), canalicular infection or canalicular surgery
- •Corneal transplant in either eye
- •Ocular surgery (such as cataract surgery or LASIK) in either eye within six months of the Baseline Visit
- •A systemic condition or disease not stabilized or judged by the investigator to be incompatible with participation in the study (e.g. current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease)
- •The history or presence of any ocular disorder or condition in either eye that, in the opinion of the investigator, would interfere with the interpretation of the study results (e.g., significant corneal or conjunctival scarring, pterygium or nodular pinguecula; current ocular infection (except mild blepharitis), conjunctivitis or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; history of ocular herpetic infection; evidence of keratoconus; lid or lacrimal cancer.
- •Active severe systemic allergy, seasonal allergies, rhinitis or sinusitis requiring changes in treatment within 30 days prior to the study or likely to require changes in treatment during the course of the study (i.e. antihistamines, decongestants, oral, topical or aerosol steroids)
- •Participation in a clinical trial during the past 30 days
- •Women who are pregnant, planning a pregnancy, or nursing at study entry.
研究组 & 干预措施
Restylane Defyne recipient
Experimental
干预措施: Restylane Defyne (Device)
结局指标
主要结局
Evaluating change in Schirmer score from baseline.
时间窗: 30 days
Maximum length of tears absorbed on test strips recorded.
次要结局
- Evaluating change in OSDI score.(30 Days)
- Evaluating change in corneal staining score.(30 Days)
- Evaluating change in dye disappearance test.(30 days)
- Evaluating change in tear break-up time.(30 days)
- Evaluating change in tear meniscus height.(30 days)
研究者
John C Meyer, MD
Ophthalmologist
The Eye Care Institute
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Study to Evaluate the Safety and Effectiveness of Restylane-Defyne for Punctual OcclusionMild to Moderate Dry Eye DiseaseNCT03709641John C Meyer, MD14
Unknown
不适用
Evaluation of Dry Eye Disease's Signs in Patients Who Were Administered Intravitreal Anti-VEGF InjectionsDry Eye SyndromesNCT06317922Francesco Bandello60
已完成
4 期
Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease PatientsDry Eye SyndromesDry EyeNCT04127851Taejoon Pharmaceutical Co., Ltd.438
已完成
不适用
Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse EnvironmentDry Eye SyndromesDry EyeNCT03097614Oculeve, Inc.57
已完成
1 期
Study of ST266 Eye Drops in Treating Dry EyeDry Eye SyndromeNCT02369861Noveome Biotherapeutics, formerly Stemnion30